-
Je něco špatně v tomto záznamu ?
Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry
RRA. Kitson, D. Kitsonová, D. Siegel, D. Ross, CJ. Moody
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
- MeSH
- benzochinony * chemie farmakologie chemická syntéza MeSH
- farmaceutická chemie metody MeSH
- lidé MeSH
- makrocyklické laktamy * chemie farmakologie chemická syntéza MeSH
- proteiny tepelného šoku HSP90 * antagonisté a inhibitory metabolismus MeSH
- protinádorové látky farmakologie chemie chemická syntéza MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Geldanamycin remains a driver in the medicinal chemistry of heat shock protein 90 (Hsp90) inhibition, even half a century after its original isolation from nature. This Perspective focuses on the properties of the benzoquinone ring of the natural product that enable a range of functionalization reactions to take place. Therefore, inherent reactivity at C-17, where the methoxy group serves as a vinylogous ester, and at C-19 that demonstrates nucleophilic, enamide-type character toward electrophiles, and also as a conjugate acceptor to react with nucleophiles, has facilitated the synthesis of semisynthetic derivatives. Thus, a range of C-17-substituted amine derivatives has been investigated in oncology applications, with a number of compounds in this series reaching clinical trials. In contrast, the 19-position of geldanamycin has received less attention, although 19-substituted derivatives offer promise with markedly reduced toxicity compared to geldanamycin itself, while retaining Hsp90 inhibitory activity albeit with diminished potency in cellular studies.
Datwyler Sealing Technologies CZ Ltd Polní 224 50401 Nový Bydžov Czech Republic
School of Chemistry University of Nottingham University Park Nottingham NG7 2RD U K
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003805
- 003
- CZ-PrNML
- 005
- 20250206104720.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.4c01048 $2 doi
- 035 __
- $a (PubMed)39361055
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kitson, Russell R A $u Department of Organic and Bioorganic Chemistry, Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
- 245 10
- $a Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry / $c RRA. Kitson, D. Kitsonová, D. Siegel, D. Ross, CJ. Moody
- 520 9_
- $a Geldanamycin remains a driver in the medicinal chemistry of heat shock protein 90 (Hsp90) inhibition, even half a century after its original isolation from nature. This Perspective focuses on the properties of the benzoquinone ring of the natural product that enable a range of functionalization reactions to take place. Therefore, inherent reactivity at C-17, where the methoxy group serves as a vinylogous ester, and at C-19 that demonstrates nucleophilic, enamide-type character toward electrophiles, and also as a conjugate acceptor to react with nucleophiles, has facilitated the synthesis of semisynthetic derivatives. Thus, a range of C-17-substituted amine derivatives has been investigated in oncology applications, with a number of compounds in this series reaching clinical trials. In contrast, the 19-position of geldanamycin has received less attention, although 19-substituted derivatives offer promise with markedly reduced toxicity compared to geldanamycin itself, while retaining Hsp90 inhibitory activity albeit with diminished potency in cellular studies.
- 650 12
- $a proteiny tepelného šoku HSP90 $x antagonisté a inhibitory $x metabolismus $7 D018841
- 650 12
- $a makrocyklické laktamy $x chemie $x farmakologie $x chemická syntéza $7 D047029
- 650 12
- $a benzochinony $x chemie $x farmakologie $x chemická syntéza $7 D016227
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a protinádorové látky $x farmakologie $x chemie $x chemická syntéza $7 D000970
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a zvířata $7 D000818
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kitsonová, Dominika $u Datwyler Sealing Technologies CZ Ltd., Polní 224, 50401 Nový Bydžov, Czech Republic
- 700 1_
- $a Siegel, David $u Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, Aurora, Colorado 80045, United States
- 700 1_
- $a Ross, David $u Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, Aurora, Colorado 80045, United States
- 700 1_
- $a Moody, Christopher J $u School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, U.K $1 https://orcid.org/000000030487041X
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 67, č. 20 (2024), s. 17946-17963
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39361055 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104716 $b ABA008
- 999 __
- $a ok $b bmc $g 2263528 $s 1239812
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 67 $c 20 $d 17946-17963 $e 20241003 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20250121